StockData
Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc. (DWTX) stock

DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.08+0.02 (+1.89%)

Close on Nov 17, 2026Market cap $36.71MP/E –Yield –

Dogwood Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Dogwood Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.78M, up 189.8% year over year. For fiscal 2025 it was $21.87M, up 519.3% from the year before. The highest annual figure on record is $21.87M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$21.87M+519.3%
FY2024Dec 31, 2024$3.53M+104.3%
FY2023Dec 31, 2023$1.73M-78.6%
FY2022Dec 31, 2022$8.07M-25.3%
FY2021Dec 31, 2021$10.80M+5464.4%
FY2020Dec 31, 2020$194.01K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.25M+26.3%
Q1 FY2026Mar 31, 2026$2.67M+9.6%
Q4 FY2025Dec 31, 2025$2.34M+0.9%
Q3 FY2025Sep 30, 2025$14.52M+2613.4%
Q2 FY2025Jun 30, 2025$2.57M+664.7%
Q1 FY2025Mar 31, 2025$2.44M+609.0%
Q4 FY2024Dec 31, 2024$2.32M+676.3%
Q3 FY2024Sep 30, 2024$535.16K+43.0%
Q2 FY2024Jun 30, 2024$336.08K-39.8%
Q1 FY2024Mar 31, 2024$343.72K-30.9%
Q4 FY2023Dec 31, 2023$298.32K-76.5%
Q3 FY2023Sep 30, 2023$374.20K-76.9%
Q2 FY2023Jun 30, 2023$557.84K-76.8%
Q1 FY2023Mar 31, 2023$497.71K-82.0%
Q4 FY2022Dec 31, 2022$1.27M-56.4%
Q3 FY2022Sep 30, 2022$1.62M-45.2%
Q2 FY2022Jun 30, 2022$2.41M-25.0%
Q1 FY2022Mar 31, 2022$2.77M+62.2%
Q4 FY2021Dec 31, 2021$2.92M+9000.4%
Q3 FY2021Sep 30, 2021$2.96M+2639.6%
Q2 FY2021Jun 30, 2021$3.21M+13661.6%
Q1 FY2021Mar 31, 2021$1.71M+5489.4%
Q4 FY2020Dec 31, 2020$32.07K–
Q3 FY2020Sep 30, 2020$108.09K–
Q2 FY2020Jun 30, 2020$23.32K–
Q1 FY2020Mar 31, 2020$30.54K–

More Dogwood Therapeutics figures

See a number that looks wrong?